Cord blood stem cells aim to fix CAR-T side effect
NCT ID NCT07212335
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This early study tests whether stem cells from donated umbilical cord blood can safely help people whose blood cell counts stay dangerously low after CAR-T cancer therapy. About 15 adults with leukemia, lymphoma, or myeloma will receive the stem cell infusion. The goal is to see if it improves red blood cells, white blood cells, and platelets without causing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.